

Ted M Burns

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10529370/publications.pdf>

Version: 2024-02-01

79
papers

4,297
citations

136740

32
h-index

114278

63
g-index

81
all docs

81
docs citations

81
times ranked

2833
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis. <i>Neurology</i> , 2022, 98, .	1.5	51
2	The Adverse Event Unit (AEU): A novel metric to measure the burden of treatment adverse events. <i>PLoS ONE</i> , 2022, 17, e0262109.	1.1	3
3	Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosis. <i>EMBO Molecular Medicine</i> , 2021, 13, e12595.	3.3	13
4	A crisis in <sc>US</sc> drug pricing: Consequences for patients with neuromuscular diseases, physicians, and society, part 2. <i>Muscle and Nerve</i> , 2020, 62, 573-578.	1.0	5
5	A crisis in <sc>US</sc> drug pricing: Consequences for patients with neuromuscular diseases, physicians and society, part 1. <i>Muscle and Nerve</i> , 2020, 62, 567-572.	1.0	7
6	Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. <i>Neurology</i> , 2020, 95, e59-e69.	1.5	119
7	Rising Drug Costs for Neurologic Diseases. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2020, 26, 1392-1406.	0.4	0
8	Cross-sectional analysis of the Myasthenia Gravis Patient Registry: Disability and treatment. <i>Muscle and Nerve</i> , 2019, 60, 707-715.	1.0	56
9	Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. <i>Neurology</i> , 2019, 92, e2661-e2673.	1.5	169
10	Chronic Acquired Polyneuropathy Patient Reported Index (CAPPRI) in chronic inflammatory demyelinating polyradiculoneuropathy. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 247-252.	1.4	5
11	Investigation of the psychometric properties of the inclusion body myositis functional rating scale with rasch analysis. <i>Muscle and Nerve</i> , 2019, 60, 161-168.	1.0	8
12	Myasthenia gravis. <i>Nature Reviews Disease Primers</i> , 2019, 5, 30.	18.1	421
13	Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. <i>Muscle and Nerve</i> , 2019, 60, 14-24.	1.0	162
14	Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis. <i>Muscle and Nerve</i> , 2019, 59, 404-410.	1.0	56
15	Estimating and managing fatigue for our patients: Are we measuring up?. <i>Muscle and Nerve</i> , 2018, 58, 182-183.	1.0	0
16	Clinical outcome assessments: The "Rasch" rationale for improved accuracy. <i>Muscle and Nerve</i> , 2018, 58, 327-329.	1.0	4
17	Validation of a simple disease-specific, quality-of-life measure for diabetic polyneuropathy. <i>Neurology</i> , 2018, 90, e2034-e2041.	1.5	6
18	Construction and validation of a novel disease-specific quality-of-life instrument for patients with primary antibody deficiency disease (PADQOL-16). <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 2007-2010.e8.	1.5	17

#	ARTICLE	IF	CITATIONS
19	Reply. Muscle and Nerve, 2017, 55, 138-140.	1.0	1
20	Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurology, The, 2017, 16, 976-986.	4.9	472
21	Rituximab as treatment for anti-MuSK myasthenia gravis. Neurology, 2017, 89, 1069-1077.	1.5	185
22	On being sick. Neurology, 2017, 89, 414-416.	1.5	1
23	International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r. Muscle and Nerve, 2016, 54, 1015-1022.	1.0	85
24	SUNCT headaches after ipsilateral ophthalmic-distribution zoster. Journal of the Neurological Sciences, 2016, 366, 207-208.	0.3	8
25	The best of both worlds: Using patient-reported plus physician-scored measures during the evaluation of myasthenia gravis. Muscle and Nerve, 2016, 53, 3-4.	1.0	12
26	Using disease-specific, patient-reported measures in everyday clinic. Neurology, 2016, 87, 858-859.	1.5	1
27	Construction and validation of the chronic acquired polyneuropathy patient-reported index (CAP-PR): A disease-specific, health-related quality-of-life instrument. Muscle and Nerve, 2016, 54, 9-17.	1.0	17
28	A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis. Neurology, 2016, 87, 57-64.	1.5	106
29	Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. Muscle and Nerve, 2016, 53, 165-168.	1.0	24
30	Two steps forward, one step back: Mycophenolate mofetil treatment for myasthenia gravis in the united states. Muscle and Nerve, 2015, 51, 635-637.	1.0	18
31	Myasthenia Gravis. Seminars in Neurology, 2015, 35, 327-339.	0.5	34
32	Quality of life measures for myasthenia gravis and evaluation of non-motor symptoms. Clinical and Experimental Neuroimmunology, 2015, 6, 32-39.	0.5	9
33	Can mycophenolate mofetil be tapered safely in myasthenia gravis? A retrospective, multicenter analysis. Muscle and Nerve, 2015, 52, 211-215.	1.0	24
34	Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis?. Muscle and Nerve, 2014, 49, 483-486.	1.0	73
35	Electrical impedance myography correlates with standard measures of Als severity. Muscle and Nerve, 2014, 49, 441-443.	1.0	61
36	The modified rankin scale to assess disability in myasthenia gravis: Comparing with other tools. Muscle and Nerve, 2014, 50, 501-507.	1.0	18

#	ARTICLE	IF	CITATIONS
37	Reply. Muscle and Nerve, 2013, 47, 145-146.	1.0	1
38	Brazilian cross-cultural translation and adaptation of the "Questionnaire of Life Quality Specific for Myasthenia Gravis - 15 items". Arquivos De Neuro-Psiquiatria, 2013, 71, 955-958.	0.3	17
39	Electrical impedance myography as a biomarker to assess ALS progression. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 439-445.	2.3	125
40	The MG composite: an outcome measure for myasthenia gravis for use in clinical trials and everyday practice. Annals of the New York Academy of Sciences, 2012, 1274, 99-106.	1.8	26
41	Quality of life and measures of quality of life in patients with neuromuscular disorders. Muscle and Nerve, 2012, 46, 9-25.	1.0	96
42	Psychometric evaluation of the myasthenia gravis composite using rasch analysis. Muscle and Nerve, 2012, 45, 820-825.	1.0	18
43	Recommendations for myasthenia gravis clinical trials. Muscle and Nerve, 2012, 45, 909-917.	1.0	122
44	More than meets the eye: The benefits of listening closely to what our patients with myasthenia gravis are telling us. Muscle and Nerve, 2012, 46, 153-154.	1.0	1
45	The Evaluation of Polyneuropathies. Neurology, 2011, 76, S6-13.	1.5	32
46	The oculobulbar facial respiratory score is a tool to assess bulbar function in myasthenia gravis patients. Muscle and Nerve, 2011, 43, 329-334.	1.0	11
47	The MG-QOL15 for following the health-related quality of life of patients with myasthenia gravis. Muscle and Nerve, 2011, 43, 14-18.	1.0	86
48	MG-ADL: Still a relevant outcome measure. Muscle and Nerve, 2011, 44, 727-731.	1.0	96
49	Clinical applications of therapeutic apheresis. Journal of Clinical Apheresis, 2010, 25, 250-264.	0.7	19
50	Construct and concurrent validation of the MG-QOL15 in the practice setting. Muscle and Nerve, 2010, 41, 219-226.	1.0	69
51	Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: Outcomes in 102 patients. Muscle and Nerve, 2010, 41, 593-598.	1.0	109
52	History of outcome measures for myasthenia gravis. Muscle and Nerve, 2010, 42, 5-13.	1.0	48
53	The MG Composite. Neurology, 2010, 74, 1434-1440.	1.5	195
54	Pearls and Oysters: Evaluation of peripheral neuropathies. Neurology, 2009, 72, e28-31.	1.5	10

#	ARTICLE	IF	CITATIONS
55	Case of the month: Leukemic nerve infiltration. Muscle and Nerve, 2009, 39, 413-414.	1.0	0
56	Less is more, or almost as much: A 15-item quality-of-life instrument for myasthenia gravis. Muscle and Nerve, 2008, 38, 957-963.	1.0	149
57	Neuroleukemiosis: Case report of leukemic nerve infiltration in acute lymphoblastic leukemia. Muscle and Nerve, 2008, 38, 1196-1200.	1.0	43
58	Construction of an efficient evaluative instrument for Myasthenia Gravis: The MG composite. Muscle and Nerve, 2008, 38, 1553-1562.	1.0	105
59	Guillain-Barré Syndrome. Seminars in Neurology, 2008, 28, 152-167.	0.5	93
60	Neuromuscular Disorders. Seminars in Neurology, 2008, 28, 131-132.	0.5	0
61	The Evaluation of Chronic Axonal Polyneuropathies. Seminars in Neurology, 2008, 28, 133-151.	0.5	13
62	The forecast for podcasts: Sunny skies but not necessarily with clear visibility. Neurology, 2007, 68, E19-E20.	1.5	18
63	Vasculitic Neuropathies. Neurologic Clinics, 2007, 25, 89-113.	0.8	45
64	Clinical Neurophysiology of Pediatric Polyneuropathies. , 2006, , 645-686.		0
65	Novel myelin protein zero mutation (Arg36Trp) in a patient with acute onset painful neuropathy. Neuromuscular Disorders, 2006, 16, 308-310.	0.3	17
66	Autonomic Testing in Childhood. , 2006, , 687-712.		0
67	An update on the classification and treatment of vasculitic neuropathy. Lancet Neurology, The, 2005, 4, 853-865.	4.9	136
68	Peripheral Neuropathies in Infants and Children: Polyneuropathies, Mononeuropathies, Plexopathies, and Radiculopathies. , 2005, , 2707-2753.		0
69	Stiff person syndrome does not always occur with maternal passive transfer of GAD65 antibodies. Neurology, 2005, 64, 399-400.	1.5	13
70	A step forward for stiff-person syndrome. Lancet, The, 2005, 365, 1365-1367.	6.3	9
71	Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Archives of Neurology, 2004, 61, 973.	4.9	16
72	Oculobulbar involvement is typical with Lambert-Eaton Myasthenic Syndrome. Annals of Neurology, 2003, 53, 270-273.	2.8	62

#	ARTICLE	IF	CITATIONS
73	Current Therapeutic Strategies for Patients With Polyneuropathies Secondary to Inherited Metabolic Disorders. Mayo Clinic Proceedings, 2003, 78, 858-868.	1.4	15
74	Neurosarcoidosis. Archives of Neurology, 2003, 60, 1166.	4.9	89
75	Clinical versus quantitative vibration assessment: improving clinical performance. Journal of the Peripheral Nervous System, 2002, 7, 112-117.	1.4	26
76	Gasoline sniffing multifocal neuropathy. Pediatric Neurology, 2001, 25, 419-421.	1.0	19
77	Adynamic ileus in severe Guillain-Barré syndrome. Muscle and Nerve, 2001, 24, 963-965.	1.0	59
78	Adynamic ileus in severe Guillain-Barré syndrome. Muscle and Nerve, 2001, 24, 963-965.	1.0	1
79	Neuroendocrine lung tumors and disorders of the neuromuscular junction. Neurology, 1999, 52, 1490-1490.	1.5	35